Goldman Sachs
ZYME icon

Goldman Sachs’s Zymeworks ZYME Stock Holding History

Goldman Sachs’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15M Buy
599,486
+179,279
+43% +$4.24M ﹤0.01% 2722
2025
Q4 		$11.1M Sell
420,207
-23,318
-5% -$509K ﹤0.01% 2999
2025
Q3 		$7.58M Buy
443,525
+14,668
+3% +$210K ﹤0.01% 3249
2025
Q2 		$5.38M Buy
428,857
+228,810
+114% +$2.73M ﹤0.01% 3340
2025
Q1 		$2.38M Sell
200,047
-49,913
-20% -$681K ﹤0.01% 4003
2024
Q4 		$3.66M Sell
249,960
-1,517
-0.6% -$21.2K ﹤0.01% 3768
2024
Q3 		$3.16M Buy
251,477
+77,876
+45% +$848K ﹤0.01% 3753
2024
Q2 		$1.48M Sell
173,601
-96,945
-36% -$863K ﹤0.01% 4159
2024
Q1 		$2.85M Buy
270,546
+69,925
+35% +$776K ﹤0.01% 3584
2023
Q4 		$2.08M Buy
200,621
+32,050
+19% +$255K ﹤0.01% 3892
2023
Q3 		$1.07M Sell
168,571
-22,306
-12% -$165K ﹤0.01% 4226
2023
Q2 		$1.65M Sell
190,877
-137,201
-42% -$1.23M ﹤0.01% 4008
2023
Q1 		$2.97M Buy
328,078
+203,021
+162% +$1.77M ﹤0.01% 3533
2022
Q4 		$983K Buy
+125,057
New +$879K ﹤0.01% 4436
2022
Q3 		– Sell
-1,179,893
Closed -$6.25M – 6569
2022
Q2 		$6.25M Buy
1,179,893
+659,457
+127% +$3.99M ﹤0.01% 2929
2022
Q1 		$3.41M Sell
520,436
-1,998,572
-79% -$17.8M ﹤0.01% 3722
2021
Q4 		$41.3M Buy
2,519,008
+2,240,800
+805% +$46.7M 0.01% 1505
2021
Q3 		$8.08M Buy
278,208
+223,823
+412% +$7.44M ﹤0.01% 2927
2021
Q2 		$1.89M Sell
54,385
-1,558
-3% -$49.4K ﹤0.01% 4260
2021
Q1 		$1.77M Buy
55,943
+40,136
+254% +$1.63M ﹤0.01% 4110
2020
Q4 		$747K Sell
15,807
-653,987
-98% -$30.4M ﹤0.01% 4387
2020
Q3 		$31.2M Buy
669,794
+513,223
+328% +$17.6M 0.01% 1381
2020
Q2 		$5.65M Buy
156,571
+75,267
+93% +$2.77M ﹤0.01% 2707
2020
Q1 		$2.88M Buy
81,304
+74,519
+1,098% +$3.05M ﹤0.01% 3056
2019
Q4 		$308K Buy
+6,785
New +$247K ﹤0.01% 4731
2018
Q4 		– Sell
-14,302
Closed -$225K – 5742
2018
Q3 		$225K Buy
+14,302
New +$205K ﹤0.01% 4859

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs's ZYME Position: Q1 2026 in Review

Goldman Sachs increased its Zymeworks (ZYME) stake by 43% in Q1 2026, buying an estimated $4.24M and bringing the position to 599,486 shares worth $15M. The position accounts for ﹤0.01% of the portfolio, ranked #2722.

Goldman Sachs first reported a position in ZYME in Q3 2018 and has held it in 26 quarters since. The position peaked at $41.3M in Q4 2021. 211 funds tracked by Wall St. Rank hold ZYME as of Q1 2026.

  • Goldman Sachs held 599,486 shares of Zymeworks worth $15M as of Q1 2026.
  • Goldman Sachs bought 179,279 Zymeworks shares in Q1 2026, an estimated $4.24M.
  • Zymeworks made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2722 holding.
  • Goldman Sachs first reported a position in Zymeworks in Q3 2018 and has held it in 26 quarters since.
  • Goldman Sachs's Zymeworks position peaked at $41.3M in Q4 2021.
  • 211 funds tracked by Wall St. Rank held Zymeworks as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.